This fact sheet provides an overview of the updated ESMO clinical practice guideline for hereditary GI cancers.
This fact sheet explains the processes involved in drug development and FDA drug approval.
This fact sheet describes some of the panels used to detect genomic aberrations and guide treatment decisions.
An FDA pooled analysis suggests that certain AEs were associated with response and overall survival in PD-1/PD-L1-treated urothelial cancer.
A synthetic control arm based on pooled historical data successfully replicated clinical outcomes.
A FAERS analysis demonstrated that osimertinib is associated with increased odds of developing cardiotoxicities compared with other EGFR TKIs.